Dupilumab StudyResearch Question:
Does dupilumab affect the immune system, water loss in the skin, and the amount of
bacteria in the skin of adults with atopic dermatitis (eczema)?
Basic Study Information
Purpose:Study Reference #: 68402
Our researchers are studying a new medication called dupilumab to determine how it
affects the immune system, water loss in the skin, and the amount of bacteria in the
skin of adults with atopic dermatitis (eczema).The Food and Drug Administration recently
approved dupilumab for the treatment of moderate-to-severe atopic dermatitis.
You will be randomized (like flipping a coin) with a 66% chance of receiving dupilumab
and 33% chance of receiving placebo for 6 weeks. After 6 weeks everyone will receive
10 weeks of dupilumab. Your skin will be checked for bacteria and barrier function
and your immune system will be monitored.
Lead Researcher (Principal Investigator)
Lead Researcher: Lisa Beck
Study Contact InformationStudy Coordinator: Jean Sauvain
Phone: (585) 275-0374
Additional Study Details
Trial Not Found
The study you are looking for is not active at this time.
Return to Search